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Non-ribosomal peptide synthetases (NRPSs) are large, modular enzymes that have an assembly line 
architecture and synthesise a diverse range of compounds such as antibiotics, siderophores and 
immunosuppressants. Within the assembly line, the peptidyl carrier protein (PCP) domain has a crucial role in 
shuttling substrates between the different catalytic domains. The PCP domain is a small four-helix bundle that 
requires a phosphopantetheinyl moiety to be attached to a conserved serine on the second alpha helix for 
functionality. This post-translational modification is catalysed by a family of enzymes called the 
phosphopantetheinyl transferases (PPTases).  
 
Due to their central role in activating enzymes involved in both primary (e.g., fatty acid synthetases) and 
secondary metabolism (e.g., NRPSs), PPTases have been identified as a promising antibiotic target in bacterial 
species such as Mycobacterium tuberculosis. We have previously developed a high-throughput enzymatic 
screen for PPTase inhibitors based on co-incubation of a target PPTase with a blue-pigment synthesising 
NRPS, BpsA. As part of the development of a complete screening platform, we also wanted to be able to rapidly 
counter-screen inhibitors for cross-inhibition of the endogenous human PPTase, as this is a potential source of 
toxicity. We found we were unable to use the native BpsA enzyme for this, as the human PPTase is incapable of 
recognising the PCP domain of BpsA.  
 
To improve with the ability of BpsA to be activated by the human PPTase, a directed evolution campaign was 
undertaken. Firstly, error-prone PCR was used to introduce mutations into the PCP domain of BpsA. 
Approximately 200,000 variants were screened using a high-throughput plate-based assay. Forty ‘hits’ were 
then characterized in a semi-quantitative liquid assay. Based on the pattern of amino acid substitutions in the 
most active variants, specific combinations of substitutions were rationally introduced into BpsA. The top variant 
identified was now capable of being rapidly phosphopantetheinylated by the human PPTase and we have 
shown this can be used to quickly screen bacterial PPTase inhibitors for cross-reactivity with the human 
PPTase. This work illustrates the flexible nature of the PCP domain and provides further evidence that only a 
few point mutations may be sufficient to dramatically change the specificity of PCP domains for different 
PPTases. 
 
